Biotech firm Regeneron starts trials for coronavirus antibody treatment

US biotech firm Regeneron Pharmaceuticals is the latest company to start clinical trials on a potential treatment for coronavirus, using antibodies produced by those who have recovered from COVID-19.

The treatment uses a combination of two antibodies to treat those sick with the virus and as a preventive measure to help inoculate those still healthy.

“We have created a unique anti-viral antibody cocktail with the potential both to prevent and treat infection,” the company’s chief scientific officer George Yancopoulos says in a statement.

Illustrative: A lab assistant in Houston, Texas holds a blood sample to be tested for COVID-19 antibodies, on April 28, 2020 (AP Photo/David J. Phillip)

Regeneron does not give a timetable for when it believes tests will be completed.

Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed